Efavirenz plasma concentrations and efficiency.
López-Cortés
L F
LF
de Alarcón
A
A
Viciana
P
P
D017088:AIDS-Related Opportunistic Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D000480:Alkynes; D019380:Anti-HIV Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D048588:Benzoxazines; D003521:Cyclopropanes; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010078:Oxazines / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016896:Treatment Outcome; D014376:Tuberculosis / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D019562:Viral Load
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz